Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT04768881 |
Title | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Newly Diagnosed or Recurrent Advanced Melanoma |
Recruitment | Terminated |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Karyopharm Therapeutics Inc |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |